Skip to main content

Table 1 Tumor and patient characteristics stratified by different groups

From: Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

Characteristics Total
n = 3761 (%)
HER2-neg
n = 3313 (%)
HER2-pos-T
n = 448 (%)
P value
Age (y/o) 55 (46–64) 56 (46–65) 51 (44–59) <  0.001
Menstrual status     <  0.001
Pre/Peri- 1562 (41.5) 1333 (40.2) 229 (51.1)  
Post- 2199 (58.5) 1980 (59.8) 219 (48.9)  
Histology type     <  0.001
IDC 3085 (82.0) 2679 (80.9) 406 (90.6)  
Non-IDC 676 (18.0) 634 (19.1) 42 (9.4)  
Histological grade     <  0.001
I/II 2395 (63.7) 164 (65.4) 231 (51.6)  
III 796 (21.2) 614 (18.5) 182 (40.6)  
NA 570 (15.1) 535 (16.1) 38 (7.8)  
Tumor size     <  0.001
≤ 2.0 cm 2251 (59.5) 2039 (61.5) 212 (47.3)  
>  2.0 cm 1510 (40.1) 1274 (38.5) 236 (52.7)  
ALN status     0.002
Negative 2415 (64.2) 2157 (65.1) 258 (57.6)  
Positive 1346 (35.8) 1156 (34.9) 190 (42.4)  
LVI     <  0.001
No 3477 (92.4) 3091 (93.3) 386 (86.2)  
Yes 284 (7.6) 222 (6.7) 62 (13.8)  
ER     <  0.001
1–9% 113 (3.0) 66 (2.0) 47 (10.5)  
10–49% 494 (13.1) 389 (11.7) 105 (23.4)  
≥ 50% 3154 (83.9) 2858 (86.3) 296 (66.1)  
PR     <  0.001
<  20% 1671 (44.4) 1363 (41.1) 308 (68.8)  
≥ 20% 2090 (55.6) 1950 (58.9) 140 (31.3)  
Ki-67     <  0.001
<  14% 1745 (46.4) 1679 (50.7) 66 (14.7)  
≥ 14% 2016 (53.6) 1634 (49.3) 382 (85.3)  
  1. HER2, human epidermal growth factor receptor 2; BCS, breast-conserving surgery; IDC, invasive ductal carcinoma; ALN, axillary lymph node; LVI, lymph-vascular invasion; ER, estrogen receptor; PR, progesterone receptor; y/o, years old